Merck’s cholesterol lowering drug gets FDA panel’s vote
A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease,...
View ArticleMerck fails to get FDA nod for new cholesterol lowering combo pill
The length of delay in approval is not clear yet as the FDA has called for additional study data on the compound. It combines generic Lipitor (Atorvastatin), the top-selling drug of all time, with...
View ArticleU.S. District Court rules in favor of Merck over ZETIA and VYTORIN patent...
Merck, known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey has ruled in Merck's favor in two jointly related patent...
View ArticleMerck full-year 2012 worldwide sales decrease 2% to $47.3 billion
Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.
View ArticleFDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection
Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of...
View ArticleJanssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for...
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A...
View ArticleRare gene mutation linked to lower cholesterol levels, reduced risk of heart...
Rare mutations that shut down a single gene are linked to lower cholesterol levels and a 50 percent reduction in the risk of heart attack, according to new research from Washington University School of...
View ArticleAdding ezetimibe to statin therapy reduces cardiovascular events
More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical...
View ArticleFDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV...
The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1...
View ArticleJanssen, Gilead to jointly develop darunavir-based, single-tablet regimen for...
Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based,...
View Article
More Pages to Explore .....